9M 2023 Financial Overview
9M 2023: APPENDIX
MAGLI program - Potential first-in-
class endocannabinoid therapy
MAGLI mode of action
28
2-AG
MAGL
OH
CB
G (ilo)
Restore neuronal
transmission
OH
Ner
ve
CB₂
2
Reduce inflammation
OH
G (ilo)
Glia
arachidonic acid
LOH
HO
HO
ОН
prostaglandin E2
OH
OH
OH
OH
prostaglandin D2 thromboxane A2
MAGL: monoacylglycerol lipase; 2-AG: 2-arachidonoylglycerol; CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2
Medical condition
•
Multiple opportunities within psychiatry and
neurology
Molecule
•
•
Inhibitor of the monoacylglycerol lipase
(MAGL) and selective modulator of the
endocannabinoid system
Clinical development phase
Clinical development program in phase I
•
Multiple assets with varying degree of
CNS penetranceView entire presentation